Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.51 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | UQCRB | P14927 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942207 | 0.87 | BRD4 (0.47) | MEN1KMT2APABPC1EIF4HBRD4 | |
| SCHEMBL3947296 | 0.87 | BRD4 (0.48) | MEN1KMT2APABPC1BRD4TRPV1 | |
| SCHEMBL3940651 | 0.86 | BRD4 (0.52) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3940902 | 0.85 | BRD4 (0.49) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3945310 | 0.85 | BRD4 (0.52) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3945664 | 0.85 | BRD4 (0.52) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3945237 | 0.84 | KMT2A (0.58) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3947425 | 0.84 | BRD4 (0.53) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL3943957 | 0.83 | NAMPT (0.61) | MEN1KMT2ABRD4TRPV1SERPINE1 | |
| SCHEMBL4116635 | 0.83 | BRD4 (0.51) | MEN1KMT2ABRD4SERPINE1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802572-B1 | INDOL DERIVATIVES AS INHIBITORS OF SOLUBLE ADENYLYL CYCLASE | BAYER SCHERING PHARMA AG (DE) | 2009-04-22 | — | — | EP | claimed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | claimed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | NGUYEN DUY | 2008-01-03 | — | — | US | disclosed |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004268-A1 | INHIBITORS OF SOLUBLE ADENYLATE CYCLASE | ADCY1, ADCY2, ADCY5 | MEN1 712/4885KMT2A 4518/4885PABPC1 1371/4885 |
| US-20060074084-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCY5 | MEN1 712/4885KMT2A 4518/4885PABPC1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.